Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,458 JPY | -2.47% | +0.55% | +2.60% |
18/04 | Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May | MT |
17/04 | Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test | MT |
Business Summary
Number of employees: 350
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 15,569 | 100.0 % | 12,766 | 100.0 % | -18.00% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
48.4
%
| 80 | 0.5 % | 6,173 | 48.4 % | +7,616.25% |
Switzerland
31.4
%
| 2,564 | 16.5 % | 4,004 | 31.4 % | +56.16% |
United States
10.8
%
| 9,934 | 63.8 % | 1,373 | 10.8 % | -86.18% |
Bermuda
9.5
%
| 2,849 | 18.3 % | 1,212 | 9.5 % | -57.46% |
United Kingdom
0.0
%
| 142 | 0.9 % | 4 | 0.0 % | -97.18% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chris Cargill
CEO | Chief Executive Officer | 40 | 20/17/20 |
Shinichi Tamura
FOU | Founder | 74 | 22/90/22 |
Director of Finance/CFO | - | 24/22/24 | |
Compliance Officer | 70 | 01/15/01 | |
Satoshi Tanaka
PRN | Corporate Officer/Principal | - | 01/23/01 |
Kieran Johnson
AUD | Comptroller/Controller/Auditor | 55 | 24/22/24 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Shinichi Tamura
FOU | Founder | 74 | 22/90/22 |
Noriaki Nagai
BRD | Director/Board Member | 66 | 27/19/27 |
Rolf Soderstrom
BRD | Director/Board Member | 58 | 25/20/25 |
Kuniaki Kaga
BRD | Director/Board Member | 72 | 22/18/22 |
Tomohiro Toyama
BRD | Director/Board Member | 74 | 01/11/01 |
David Roblin
BRD | Director/Board Member | 57 | 22/18/22 |
Chris Cargill
CEO | Chief Executive Officer | 40 | 20/17/20 |
Miwa Seki
BRD | Director/Board Member | 59 | 24/22/24 |
Eiko Tomita
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 89,446,777 | 79,495,767 ( 88.87 %) | 335 ( 0.000375 %) | 88.87 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
929,353 | 1.03% | 10,501,689 $ | |
BIOHAVEN LTD. 0.03% | 27,308 | 0.03% | 1,493,475 $ |
NXERA PHARMA CO., LTD. 0.00% | 300 | 0.00% | 3,294 $ |
Company contact information
Sosei Group Corp.
PMO Hanzomon, 11/F 2-1 Koji-machi
102-0083, Tokyo
+81 3 5210 3290
https://soseiheptares.comGroup companies
Name | Category and Sector |
---|---|
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. |
Pharmaceuticals: Major
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.60% | 828M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 4565 Stock
- Company Nxera Pharma Co., Ltd.